Statistical Health Monitoring Applied to a Metabolomic Study of Experimental Hepatocarcinogenesis: An Alternative Approach to Supervised Methods for the Identification of False Positives.

In a typical metabolomics experiment, two or more conditions (e.g., treated versus untreated) are compared, in order to investigate the potential differences in the metabolic profiles. When dealing with complex biological systems, a two-class classification is often unsuitable, since it does not consider the unpredictable differences between samples (e.g., nonresponder to treatment). An approach based on statistical process control (SPC), which is able to monitor the response to a treatment or the development of a pathological condition, is proposed here. Such an approach has been applied to an experimental hepatocarcinogenesis model to discover early individual metabolic variations associated with a different response to the treatment. Liver study was performed by nuclear magnetic resonance (NMR) spectroscopy, followed by multivariate statistical analysis. By this approach, we were able to (1) identify which treated samples have a significantly different metabolic profile, compared to the control (in fact, as confirmed by immunohistochemistry, the method correctly classified 7 responders and 3 nonresponders among the 10 treated animals); (2) recognize, for each individual sample, the metabolites that are out of control (e.g., glutathione, acetate, betaine, and phosphocholine). The first point could be used for classification purposes, and the second point could be used for a better understanding of the mechanisms underlying the early phase of carcinogenesis. The statistical control approach can be used for diagnosis (e.g., healthy versus pathological, responder versus nonresponder) and for generation of an individual metabolic profile, leading to a better understanding of the individual pathological processes and to a personalized diagnosis and therapy.

[1]  M. Turner,et al.  A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis , 2014, Neurology.

[2]  R. Brereton,et al.  Partial least squares discriminant analysis: taking the magic away , 2014 .

[3]  John C Lindon,et al.  Statistical total correlation spectroscopy scaling for enhancement of metabolic information recovery in biological NMR spectra. , 2012, Analytical chemistry.

[4]  Ara W. Darzi,et al.  Metabolic phenotyping in clinical and surgical environments , 2012, Nature.

[5]  R. Kauppinen,et al.  1H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice , 2010, British Journal of Cancer.

[6]  G. M. Ledda-Columbano,et al.  Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. , 2000, Cancer research.

[7]  J. Griffin,et al.  Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor δ from Peroxisome proliferator-activated receptor γ in the ob/ob mouse , 2009, Genome Medicine.

[8]  S. Giordano,et al.  MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. , 2014 .

[9]  Xin Lu,et al.  A weighted relative difference accumulation algorithm for dynamic metabolomics data: long-term elevated bile acids are risk factors for hepatocellular carcinoma , 2015, Scientific Reports.

[10]  T. Ebbels,et al.  NMR-based metabolic profiling identifies biomarkers of liver regeneration following partial hepatectomy in the rat. , 2010, Journal of proteome research.

[11]  J. Griffin,et al.  Does Our Gut Microbiome Predict Cardiovascular Risk?: A Review of the Evidence From Metabolomics , 2015, Circulation. Cardiovascular genetics.

[12]  L. Barberini,et al.  Pharma-metabolomics in neonatology: is it a dream or a fact? , 2012, Current pharmaceutical design.

[13]  J. Huse,et al.  Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. , 2013, Journal of neuropathology and experimental neurology.

[14]  R. A. van den Berg,et al.  Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.

[15]  C. Newgard,et al.  Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. , 2015, Circulation. Cardiovascular genetics.

[16]  Xuefeng Yan,et al.  Chemical processes monitoring based on weighted principal component analysis and its application , 2012 .

[17]  M. Rantalainen,et al.  OPLS discriminant analysis: combining the strengths of PLS‐DA and SIMCA classification , 2006 .

[18]  A. Chinnaiyan,et al.  Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. , 2011, Journal of proteome research.

[19]  Oliver A.H. Jones Metabolomics and systems biology in human health and medicine. , 2014 .

[20]  S. Williams,et al.  A comparison of cell and tissue extraction techniques using high‐resolution 1H‐NMR spectroscopy , 2002, NMR in biomedicine.

[21]  S. Joe Qin,et al.  Statistical process monitoring: basics and beyond , 2003 .

[22]  D. Wishart,et al.  Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.

[23]  Age K. Smilde,et al.  Generalized contribution plots in multivariate statistical process monitoring , 2000 .

[24]  S. Joe Qin,et al.  Analysis and generalization of fault diagnosis methods for process monitoring , 2011 .

[25]  Peiyuan Yin,et al.  Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis , 2014, Analytical and Bioanalytical Chemistry.

[26]  A. Weljie,et al.  Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. , 2011, The international journal of biochemistry & cell biology.

[27]  O. Feron,et al.  Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer , 2015, Current opinion in clinical nutrition and metabolic care.

[28]  A. Smilde,et al.  Assessing the statistical validity of proteomics based biomarkers. , 2007, Analytica chimica acta.

[29]  Johan Trygg,et al.  Chemometrics in metabonomics. , 2007, Journal of proteome research.

[30]  D. Gauguier,et al.  Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.

[31]  Lutgarde M. C. Buydens,et al.  Towards the Disease Biomarker in an Individual Patient Using Statistical Health Monitoring , 2014, PloS one.

[32]  M. Pibiri,et al.  Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype , 2009, Hepatology.

[33]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[34]  S. Giordano,et al.  MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC) , 2014, Hepatology.

[35]  Theodora Kourti,et al.  Statistical Process Control of Multivariate Processes , 1994 .